ARCHIVED - EMA meeting on March 11 to evaluate Janssen vaccine for use in Europe
If the authorisation goes ahead as hoped, this will give Spain a fourth vaccine and speed up the vaccination process
As the coronavirus vaccination campaign in Spain and other EU countries continues to gather momentum slowly the European Medicines Agency is close to completing its evaluation of the Janssen vaccine, produced by the Belgian subsidiary of the American pharmaceuticals company Johnson & Johnson.
The EMA experts are set to meet on 11th March to reach their final conclusions regarding the safety, efficiency and quality of the Janssen product, and if their verdict is a positive one then the recommendation will be made for the European Commission to grant a licence for its widespread use among the general population. This would make the Janssen the fourth to gain the approval of the EMA, following those produced by Pfizer, Moderna and AstraZeneca.